Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS
Contenu archivé le 2024-06-16

General synthetic strategies towards heterocyclic compounds via transition metal-catalysed reactions

Objectif

The reasoning behind the HCTMCR project is the need to develop mild and regioselective synthetic routes for the preparation of heterocyclic compounds. Decorated heterocyclic scaffolds are very important as biologically active compounds in the drug discover y process. However, many traditional routes for the synthesis of heterocycles are not compatible with a variety of functional groups or substitution patterns. The work carried out within the HCTMCR research project is geared towards the discovery of new, i nnovative synthetic strategies that will overcome existing limitations and will make accessible a multitude of heterocyclic structures. One approach to achieving this goal will be the application of modern organometallic reactions, such as metal-catalyzed cross-coupling reactions or olefin metathesis. Thus, heterocycles such as substituted 1H- and 2H-indazoles, benzimidazoles, 2H-chromenes or quinolines will be accessible in a regioselective manner, as well as annulated heterocycles of various ring sizes. I n addition, microwave technology will be applied when necessary to optimize the respective reaction time and yield. Another aspect of the investigations performed within the HCTMCR project will be the use of readily available starting materials in a conver gent fashion. Thus, regioselective aromatic C-H bond activation or the activation of chlorine-substituted aromatic systems as one of the reaction partners will be studied. If applicable, the development of multi-component pathways will be pursued.

Champ scientifique (EuroSciVoc)

Thème(s)

Appel à propositions

FP6-2002-MOBILITY-3
Voir d’autres projets de cet appel

Régime de financement

TOK - Marie Curie actions-Transfer of Knowledge

Coordinateur

AVENTIS PHARMA DEUTSCHLAND GMBH
Contribution de l’UE
Aucune donnée
Adresse
Industriepark Hoechst, Building H821
FRANKFURT AM-MAIN
Allemagne
Coût total
Aucune donnée